secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001558370-24-002306
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 2.04, 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus completes CIMERLI ophthalmology sale to Sandoz for $170M cash; repays $175M debt
--------------------------------------------------------------------------------

- Closed sale of CIMERLI franchise to Sandoz for upfront $170M cash plus $17.8M for inventory and prepaid manufacturing assets.
- Proceeds used to partially repay $175M of $250M term loan principal on or before April 1, 2024, plus $6.8M premium and makewhole.
- Transaction sharpens strategic focus on oncology; CIMERLI BLA, sales team, and commercial software transferred.
- Pro forma net loss for nine months ended Sep 30, 2023 would have been $196M versus historical $158M; loss per share $1.97 vs $1.79.
- Cash and equivalents pro forma $77.7M after debt paydown and disposition adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024002306/0001558370-24-002306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024002306/chrs-20240301x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-002306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer